# OnCo record blossomhill-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/blossomhill-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "blossomhill-therapeutics" ;
  schema:name "BlossomHill Therapeutics"@en ;
  schema:description "BlossomHill Therapeutics designs pills against cancer mutations and pathways that current drugs miss: BH-30643 for EGFR-mutant lung cancer that has stopped responding, BH-30236 for acute myeloid leukaemia and higher-risk myelodysplastic syndromes, and a pan-KRAS drug heading for trials in 2027."@en ;
  schema:url <https://onco.cc/companies/blossomhill-therapeutics/>, <https://www.bhtherapeutics.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.bhtherapeutics.com/>, <https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001839970>, <https://ir.bhtherapeutics.com/>, <https://www.sec.gov/Archives/edgar/data/1839970/000119312526340215/d98958d424b4.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/mds-higher-risk/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/colorectal/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/kras/> .